Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
A1ATD Investors
Andover, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
A1ATD Investors is a venture capital investment firm based in Andover, Massachusetts, that specializes in the life sciences and biotechnology sectors. Founded in 2017 by the late Edward Krapels, the firm focuses on funding innovative research and therapeutic development for rare genetic disorders, with a primary emphasis on Alpha-1 Antitrypsin Deficiency (A1ATD). The firm is a key investor in Apic Bio, supporting the advancement of gene therapy platforms like THRIVE for treating A1ATD and Amyotrophic Lateral Sclerosis (ALS). A1ATD Investors serves as a strategic investment vehicle dedicated to addressing significant unmet medical needs through targeted capital allocation in the biotech industry.
- Therapeutic areas
- NeurologyRare Diseases
- Industry
- Investors
02
Partnerships
Apic BioAlpha-1 FoundationALS Investment FundMorningside Venture Investments
Beyond the preview
Go deeper on A1ATD Investors.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A1ATD Investors.